PremiumThe FlyHutchmed reports FY24 EPS 22c vs. 59c last year Hutchmed/Innovent update on Phase 2/3 study of Fruquintinib+Sintilimab Hutchmed completes enrollment of fanregratinib trial PremiumThe FlyMorning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint Hutchmed announces NDA acceptance in China, payment from AstraZeneca Hutchmed divests 45% interest in Shanghai Hutchison for $608M PremiumThe FlyHutchmed announces new, updated data from sovleplenib ESLIM-01 trial Hutchmed to receive $20M milestone payment from Takeda for Fruzaqla sales Hutchmed announces results from SAVANNAH trial 
